期刊
EUROPEAN JOURNAL OF NEUROLOGY
卷 23, 期 -, 页码 18-27出版社
WILEY
DOI: 10.1111/ene.12883
关键词
disease-modifying; multiple sclerosis; review; treatment
资金
- Genzyme
- Merck-Serono
- Novartis
- Biogen Idec
- Bayer
- Sanofi-Aventis
- Pronova Biocare
- Norwegian MS Society
Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing - remitting MS (RRMS). Methods: A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015. Results: In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed. Conclusions: Based on current knowledge of risk - benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk - benefit stratification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据